Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

First Nations hepatitis C virus infections: Six-year retrospective study of on-reserve rates of newly reported infections in northwestern Ontario.

Gordon J, Bocking N, Pouteau K, Farrell T, Ryan G, Kelly L.

Can Fam Physician. 2017 Nov;63(11):e488-e494.

2.

Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M.

Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021. doi: 10.1002/14651858.CD012021.pub2. Review.

3.

Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis.

Davis SM, Daily S, Kristjansson AL, Kelley GA, Zullig K, Baus A, Davidov D, Fisher M.

Harm Reduct J. 2017 May 17;14(1):25. doi: 10.1186/s12954-017-0156-z.

4.

Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.

Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, Cox AL, Dore G, Grebely J, Kim AY, Lauer GM, Lloyd A, Rice T, Shoukry N, Maher L, Page K; International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3).

Clin Infect Dis. 2017 Apr 1;64(7):860-869. doi: 10.1093/cid/ciw869.

5.

Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study.

McFall AM, Solomon SS, Lucas GM, Celentano DD, Srikrishnan AK, Kumar MS, Mehta SH.

Addiction. 2017 Aug;112(8):1480-1487. doi: 10.1111/add.13821. Epub 2017 Apr 18.

PMID:
28317210
6.

Alcohol use in opioid agonist treatment.

Nolan S, Klimas J, Wood E.

Addict Sci Clin Pract. 2016 Dec 8;11(1):17. Review.

7.

Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.

Jacka B, Applegate T, Poon AF, Raghwani J, Harrigan PR, DeBeck K, Milloy MJ, Krajden M, Olmstead A, Joy JB, Marshall BD, Hayashi K, Pybus OG, Lima VD, Magiorkinis G, Montaner J, Lamoury F, Dore GJ, Wood E, Grebely J.

J Hepatol. 2016 Jun;64(6):1247-55. doi: 10.1016/j.jhep.2016.02.031. Epub 2016 Feb 26.

8.
9.

Risk environments facing potential users of a supervised injection site in Ottawa, Canada.

Shaw A, Lazarus L, Pantalone T, LeBlanc S, Lin D, Stanley D, Chepesiuk C, Patel S, Tyndall M; PROUD Community Advisory Committee.

Harm Reduct J. 2015 Oct 22;12:49. doi: 10.1186/s12954-015-0083-9.

10.

Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.

Todd CS, Nasir A, Stanekzai MR, Fiekert K, Sipsma HL, Vlahov D, Strathdee SA.

Harm Reduct J. 2015 Oct 16;12:22. doi: 10.1186/s12954-015-0056-z.

11.

Exploring the Public Health Impacts of Private Security Guards on People Who Use Drugs: a Qualitative Study.

Markwick N, McNeil R, Small W, Kerr T.

J Urban Health. 2015 Dec;92(6):1117-30. doi: 10.1007/s11524-015-9992-x.

12.

Misplaced advocacy: What does better hepatitis C treatment really mean?

Tyndall M.

CMAJ. 2015 Oct 20;187(15):1111-2. doi: 10.1503/cmaj.150612. Epub 2015 Aug 4. No abstract available.

13.

Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada.

Cunningham EB, Jacka B, DeBeck K, Applegate TL, Harrigan PR, Krajden M, Marshall BD, Montaner J, Lima VD, Olmstead AD, Milloy MJ, Wood E, Grebely J.

Drug Alcohol Depend. 2015 Jul 1;152:272-6. doi: 10.1016/j.drugalcdep.2015.04.005. Epub 2015 Apr 20.

14.

Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Arain A, Robaeys G.

World J Gastroenterol. 2014 Sep 28;20(36):12722-33. doi: 10.3748/wjg.v20.i36.12722. Review.

15.
16.

Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada.

Jacka B, Applegate T, Krajden M, Olmstead A, Harrigan PR, Marshall B, DeBeck K, Milloy MJ, Lamoury F, Pybus OG, Lima VD, Magiorkinis G, Montoya V, Montaner J, Joy J, Woods C, Dobrer S, Dore GJ, Poon AF, Grebely J.

Hepatology. 2014 Nov;60(5):1571-1580. doi: 10.1002/hep.27310. Epub 2014 Sep 29.

17.

Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012.

Grebely J, Lima VD, Marshall BD, Milloy MJ, DeBeck K, Montaner J, Simo A, Krajden M, Dore GJ, Kerr T, Wood E.

PLoS One. 2014 Jun 4;9(6):e97726. doi: 10.1371/journal.pone.0097726. eCollection 2014.

18.

Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort.

Tracy D, Hahn JA, Fuller Lewis C, Evans J, BriceƱo A, Morris MD, Lum PJ, Page K.

BMJ Open. 2014 May 29;4(5):e004988. doi: 10.1136/bmjopen-2014-004988.

19.

The epidemiology of hepatitis C in a Canadian Indigenous population.

Uhanova J, Tate RB, Tataryn DJ, Minuk GY.

Can J Gastroenterol. 2013 Jun;27(6):336-40.

20.

A method for killer-cell immunoglobulin-like receptor (KIR) 3DL1/3DS1 genotyping using DNA recovered from frozen plasma.

Shahid A, Chopera DR, Martin E, Penney KA, Milloy MJ, Brumme ZL.

J Immunol Methods. 2013 May 31;391(1-2):154-62. doi: 10.1016/j.jim.2013.03.005. Epub 2013 Mar 21.

Supplemental Content

Support Center